MRK•benzinga•
Reported Sunday, Merck's Phase 3 KEYNOTE-689 Data Shows KEYTRUDA Significantly Improves Event-Free Survival As Perioperative Therapy In Locally Advanced Head And Neck Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2025 by benzinga